Of Interest

Bently P. Doonan, MD, discusses the utility of oncolytic viruses and the need for novel treatments after checkpoint inhibitors in advanced melanoma.

Elizabeth Buchbinder, MD, discusses the implications of the FDA’s decision to grant breakthrough therapy designation to RP1 plus nivolumab in melanoma.

Vaccines for treating and preventing cancer have long been considered a holy grail in oncology.

A significant vertical gradient in cutaneous malignant melanoma density has been identified, as melanoma density is notably higher in upper body regions like the face and ears than in lower body areas. Published in Skin Health and Disease, the study findings highlight the need for targeted sun protection strategies, particularly for high-risk areas frequently exposed to sunlight.